Our findings align with previous studies demonstrating that PD patients with severe RBD, cognitive impairment, hyposmia, and dopaminergic deficits on DAT imaging exhibit faster clinical progression (Pagano et al., 2018; Schrag et al., 2017). Here, SLC6A3 is linked to Cognitive impairment.